Black Diamond Therapeutics Inc
NASDAQ:BDTX

Watchlist Manager
Black Diamond Therapeutics Inc Logo
Black Diamond Therapeutics Inc
NASDAQ:BDTX
Watchlist
Price: 2.81 USD 1.08% Market Closed
Market Cap: 160.1m USD

Net Margin
Black Diamond Therapeutics Inc

30.7%
Current
4%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
30.7%
=
Net Income
21.5m
/
Revenue
70m

Net Margin Across Competitors

No Stocks Found

Black Diamond Therapeutics Inc
Glance View

Market Cap
160m USD
Industry
Biotechnology

Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 88 full-time employees. The company went IPO on 2020-01-30. The firm is focused on the discovery and development of small molecule, MasterKey therapies. The Company’s technology platform, Mutation-Allostery-Pharmacology (MAP) platform, is designed to allow it to analyze population-level genetic sequencing data to discover oncogenic mutations that promote cancer across tumor types. Its lead product candidate, BDTX-189, is designed as an orally available, irreversible small molecule inhibitor that targets a spectrum of 48 non-canonical and canonical driver mutations of the ErbB kinases epidermal growth factor receptor (EGFR) and HER2. BDTX-1535 is designed as a brain-penetrant small molecule inhibitor that targets a spectrum of EGFR mutations, including allosteric and canonical mutations. The company also has early-stage programs, such as B-Raf Proto-Oncogene (BRAF), and fibroblast growth factor receptor (FGFR).

BDTX Intrinsic Value
9.41 USD
Undervaluation 70%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
30.7%
=
Net Income
21.5m
/
Revenue
70m
What is the Net Margin of Black Diamond Therapeutics Inc?

Based on Black Diamond Therapeutics Inc's most recent financial statements, the company has Net Margin of 30.7%.

Back to Top